Last checked at 8 Jun 2023 13:31
GENinCode Plc
("GENinCode" or the "Company")
Posting of Annual Report to Shareholders and Notice of Annual General Meeting
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, confirms that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of Annual General Meeting ("AGM") have been posted to shareholders.
A copy of the 2022 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20:
https://investors.genincode.com/investors
The AGM will be held in person at the offices of Cenkos Securities plc, 6,7,8 Tokenhouse Yard, London EC2R 7AS on Friday, 30 June 2023 at 2.00 p.m.
For more information visit www.genincode.com
Enquiries:
GENinCode Plc | www.genincode.com or via Walbrook PR | ||
Matthew Walls, CEO | |||
Paul Foulger, CFO
| |||
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | ||
Alex Price / Ben Maddison / Richard Short | |||
Cenkos Securities Plc (Joint Broker) |
Tel: +44 (0)20 7397 8900 | ||
Giles Balleny | |||
Dale Bellis / Michael Johnson (Sales) | |||
Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage |
Tel: 020 7933 8780 or genincode@walbrookpr.com | ||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.
About Cardiovascular Disease (CVD):
CVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas with the NHS 10 Year Plan identifying CVD as the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.
Early detection and treatment of CVD can help patients live longer, healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year Plan is working towards people knowing and managing risks around their 'ABC' (AF, Blood pressure and Cholesterol).